Jack W. Callicutt - 03 Nov 2025 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Role
Chief Financial Officer
Signature
Jack W. Callicutt
Issuer symbol
GALT
Transactions as of
03 Nov 2025
Net transactions value
-$144,468
Form type
4
Filing time
05 Nov 2025, 16:06:19 UTC
Previous filing
15 Sep 2025
Next filing
07 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
CALLICUTT JACK W Chief Financial Officer C/O GALECTIN THERAPEUTICS INC., 4960 PEACHTREE INDUSTRIAL BLVD., STE 240, NORCROSS Jack W. Callicutt 05 Nov 2025 0001266773

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GALT Common Stock Options Exercise $2,574 +1,300 +17% $1.98 8,914 03 Nov 2025 Direct F1
transaction GALT Common Stock Sale $7,813 -1,300 -15% $6.01 7,614 03 Nov 2025 Direct F1, F2
transaction GALT Common Stock Options Exercise $1,399 +1,260 +17% $1.11 8,874 03 Nov 2025 Direct F1
transaction GALT Common Stock Sale $7,573 -1,260 -14% $6.01 7,614 03 Nov 2025 Direct F1, F2
transaction GALT Common Stock Options Exercise $2,150 +1,250 +16% $1.72 8,864 03 Nov 2025 Direct F1
transaction GALT Commno stock Sale $7,512 -1,250 -14% $6.01 7,614 03 Nov 2025 Direct F1, F2
transaction GALT Common stock Options Exercise $17,650 +8,914 +117% $1.98 16,528 04 Nov 2025 Direct F1
transaction GALT Common stock Sale $54,108 -8,914 -54% $6.07 7,614 04 Nov 2025 Direct F1, F6
transaction GALT Common stock Options Exercise $9,961 +8,974 +118% $1.11 16,588 04 Nov 2025 Direct F1
transaction GALT Common stock Sale $54,472 -8,974 -54% $6.07 7,614 04 Nov 2025 Direct F1, F6
transaction GALT Common stock Options Exercise $18,475 +10,741 +141% $1.72 18,355 04 Nov 2025 Direct F1
transaction GALT Common stock Sale $65,198 -10,741 -59% $6.07 7,614 04 Nov 2025 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GALT Stock option (right to buy) Options Exercise $0 -1,300 -2.6% $0.000000 48,700 03 Nov 2025 Common Stock 1,300 $1.98 Direct F1, F3
transaction GALT Stock option (right to buy) Options Exercise $0 -1,260 -2.5% $0.000000 48,740 03 Nov 2025 Common Stock 1,260 $1.11 Direct F1, F4
transaction GALT Stock option (right to buy) Options Exercise $0 -1,250 -1.9% $0.000000 63,750 03 Nov 2025 Comm stock 1,250 $1.72 Direct F1, F5
transaction GALT Stock option (right to buy) Options Exercise $0 -8,914 -18% $0.000000 39,786 04 Nov 2025 Common stock 8,914 $1.98 Direct F1, F3
transaction GALT Stock option (right to buy) Options Exercise $0 -8,974 -18% $0.000000 39,766 04 Nov 2025 Common stock 8,974 $1.11 Direct F1, F4
transaction GALT Stock option (right to buy) Options Exercise $0 -10,741 -17% $0.000000 53,009 04 Nov 2025 Common stock 10,741 $1.72 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.
F2 The shares were sold in multiple transactions at prices ranging from $6.00 to $6.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3 The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023.
F4 The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024.
F5 The options vested as follows: 25% on each of June 30, 2024, December 31, 2024, and June 30, 2025, with 25% scheduled to vest on December 31, 2025.
F6 The shares were sold in multiple transactions at prices ranging from $6.00 to $6.25. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.